Shareholder Lawsuit Opportunity Against Vistagen Therapeutics (VTGN)

LOS ANGELES — Investors who suffered financial losses on shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) now have a chance to take an active role in a class action securities lawsuit being handled by the Schall Law Firm, a national shareholder rights litigation firm.

Background of the Case

The lawsuit alleges that Vistagen violated federal securities laws by making false and misleading statements to the market concerning the progress and prospects of its drug candidate fasedienol during its Phase 3 PALISADE-2 clinical trial.

According to the complaint, the company gave investors the impression that the PALISADE-2 trial was on track for success and downplayed the risks of potential failure. These statements are claimed to have been materially misleading, because when the true results and risks became known to the public, the market reacted negatively, resulting in investor losses.

Class Period and Eligibility

The proposed class includes all persons and entities that purchased or otherwise acquired Vistagen Therapeutics securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). Investors who fit this description and suffered losses are encouraged to consider their rights in the case.

Deadline for Lead Plaintiff Motion

Investors who wish to be considered for the role of lead plaintiff — a position that can provide greater influence and oversight of the litigation — must act before March 16, 2026.

What Representation Means

Until the class action is certified by the court, class members are not represented by legal counsel. Individuals may choose to remain absent class members and take no action, but doing so may limit their involvement in decisions about the lawsuit’s direction.

Contacting the Schall Law Firm does not automatically enroll an investor in the lawsuit; rather, it starts a discussion about rights and potential participation.

Allegations Against Vistagen Therapeutics

The complaint asserts that Vistagen’s public disclosures misrepresented key facts related to its drug development programs and clinical trial results. Specifically, the firm alleges that:

• Investors were led to believe that Phase 3 results for fasedienol were more favorable than they actually were.
• The risks associated with the PALISADE-2 trial were minimized or mischaracterized in official statements.
• Once the truth was revealed, the market adjusted accordingly, leading to financial harm for shareholders.

About the Schall Law Firm

The Schall Law Firm represents investors globally in securities class action and shareholder rights litigation. The firm specializes in cases where corporate disclosures may have violated securities laws, causing financial harm to public shareholders.

Those interested in learning more or discussing their legal options may contact the firm directly.

How to Participate

Investors seeking to participate and discuss possible losses can reach out to the Schall Law Firm for a free consultation. Contact details typically include phone, email, and an online contact form hosted on the firm’s website.

Important Considerations for Investors

Class actions involving securities fraud can take significant time to resolve, and participating investors should carefully consider the implications, including potential recovery timelines and legal representation options.

Being part of the class action does not guarantee financial recovery, but it allows affected shareholders to seek compensation for their losses as part of a group.

#VistagenTherapeutics #VTGN #SecuritiesFraud #InvestorRights #SlimScan #GrowthStocks #CANSLIM